The Platinum(II) Complexes Induced Oxidative Stress of Isolated Rat Heart

1. Bruijnincx PC, Sadler PJ. New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 2008; 12(2): 197-206.10.1016/j.cbpa.2007.11.013292302918155674Search in Google Scholar

2. van Rijt SH, Sadler PJ. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov Today 2009; 14(23-24): 1089-97, DOI: 10.1016/j.drudis.2009.09.003.10.1016/j.drudis.2009.09.003293382319782150Search in Google Scholar

3. Oun R, Wheate NJ. Platinum Anticancer Drugs. In: Kretsinger RH, Uversky VN, Permiyakov EA: Encyclopedia of Metalloproteins. New York, Heidelberg, Dordrecht, London: Springer 2013: pp.1710-14.10.1007/978-1-4614-1533-6_525Search in Google Scholar

4. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Peres JM. Biochemical Mechanisms of Cisplatin Cytotoxicity. Anticancer Agents Med Chem 2007; 7(1): 3-18.10.2174/18715200777931404417266502Search in Google Scholar

5. Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, Osanto S. Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 1998; 9(12): 1331–7.10.1023/A:1008407014084Search in Google Scholar

6. Jung Y, Lippard SJ. Direct cellular responses to platinum induced DNA damage. Chem Rev 2007; 107: 1387-1407.10.1021/cr068207j17455916Search in Google Scholar

7. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33(1): 9–23.10.1016/j.ctrv.2006.09.006185522217084534Search in Google Scholar

8. van Zutphen S, Reedijk J. Targeting platinum anti-tumour drugs: overview of strategies employed to reduce systemic toxicity. Coord Chem Rev 2005; 249: 2845-53.10.1016/j.ccr.2005.03.005Search in Google Scholar

9. Barry NP, Sadler PJ. Exploration of the medical periodic table: towards new targets. Chem Commun (Camb) 2013; 49: 5106-31.10.1039/c3cc41143e23636600Search in Google Scholar

10. Pai V, Nahata M. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000; 22(4): 263–302.10.2165/00002018-200022040-0000210789823Search in Google Scholar

11. Patanè S. Cardiotoxicity: cisplatin and long-term cancer survivors. Int J Cardiol 2014; 175(1): 201–2.10.1016/j.ijcard.2014.04.238Search in Google Scholar

12. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res 2006; 53(3): 278–86.10.1016/j.phrs.2005.12.005Search in Google Scholar

13. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ et al. Cardiovascular morbidity in long term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725 32.10.1200/JCO.2000.18.8.1725Search in Google Scholar

14. Kucharz J, Michalowska-Kaczmarczyk A, Zygulska A, Wojtak J et al. Bradycardia as a rare symptom of cisplatin cardiotoxicity: a case report. Oncol Lett 2016; 11(3): 2297-99.10.3892/ol.2016.4195Search in Google Scholar

15. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: The need for Cardio-Oncology and Cardio-Oncological Prevention. J Natl Cancer Inst 2010; 102:14–25.10.1093/jnci/djp440Search in Google Scholar

16. Minotti G, Salvatorelli E, Menna P. Pharmacological foundations of cardio-oncology. J Pharmacol Exp Ther 2010; 334: 2–8.10.1124/jpet.110.165860Search in Google Scholar

17. Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009; 61(3): 223-42.10.1016/j.etp.2008.09.003Search in Google Scholar

18. Hussein A, Ahmed AA, Shouman SA, Sharawy S. Ameliorating effect of DL-a-lipoic acid against cisplatin-induced nephrotoxicity and cardiotoxicity in experimental animals. Drug Discov Ther 2012; 6(3): 147–56.10.5582/ddt.2012.v6.3.147Search in Google Scholar

19. Auclair C, Voisin E. Nitroblue tetrazolium reduction. In: Greenvvald RA (Ed.): Handbook of methods for oxygen radical research. CRC Press, Boca Raton 1985; 123–32.Search in Google Scholar

20. Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980; 38: 161–70.10.1016/0022-1759(80)90340-3Search in Google Scholar

21. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem 1982; 126(1): 131–8.10.1016/0003-2697(82)90118-XSearch in Google Scholar

22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95(2): 351–8.10.1016/0003-2697(79)90738-3Search in Google Scholar

23. Galanski M, Keppler BK. Synthesis and characterization of new ethylendiamine platinum (IV) complexes containing lipophilic carboxylate ligands. Metal Based Drugs 1995; 2: 57-63.10.1155/MBD.1995.57Search in Google Scholar

24. Ma H, Jones KR, Guo R, Xu P, Shen Y, Ren J. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol 2010; 37: 460-5.10.1111/j.1440-1681.2009.05323.xSearch in Google Scholar

25. Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, Abete P et al. Platinum-based compounds and risk for cardiovascular toxicity in elderly: role of the antioxidants in chemoprevention. Rejuvenation Res 2011; 14: 293-308.10.1089/rej.2010.1141Search in Google Scholar

26. El-Awady ES, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650: 335–41.10.1016/j.ejphar.2010.09.085Search in Google Scholar

27. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999; 84: 257-65.10.1161/01.RES.84.3.257Search in Google Scholar

28. Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002; 13: 858-65.10.1681/ASN.V134858Search in Google Scholar

29. Devarajan P, Savoca M, Castaneda MP, Park MS, Esteban-Cruciani N, Kalinec G et al. Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Heart Res 2002; 17: 45-54.10.1016/S0378-5955(02)00634-2Search in Google Scholar

30. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 2015; 309(9): H1453-67.10.1152/ajpheart.00554.2015466697426386112Search in Google Scholar

31. Martins NM, Santos NA, Curti C, Bianchi ML, Santos AC. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol 2008; 28(3): 337-44.10.1002/jat.128417604343Search in Google Scholar

32. Yuce A, Atessahin A, Ceribasi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 2007; 101(5): 345-9.10.1111/j.1742-7843.2007.00129.xSearch in Google Scholar

33. Halliwell B. Reactive species and antioxidants. Redox biology is a fundamental theme of aerobic life. Plant Physiol 2006; 141: 312-22.10.1104/pp.106.077073Search in Google Scholar

34. Nakhaee A, Bokaeian M, Noori S, Mahboob T. Antioxidant effect of carnosine pretreatment on cisplatin-induced renal oxidative stress in rats. Indian J Clin Biochem 2010; 25: 86–91.10.1007/s12291-010-0018-xSearch in Google Scholar

35. Jakupec MA, Galanski M, Keppler BK. Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003; 146: 1-53.10.1007/s10254-002-0001-xSearch in Google Scholar

36. Baek SM, Kwon CH, Kim JH, Woo Js, Jung JS, Kim YK. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003; 142(3): 178-86.10.1016/S0022-2143(03)00111-2Search in Google Scholar

37. Demkow U, Stelmaszczyk-Emmel A. Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Respir Physiol Neurobiol 2013; 187:64-7.10.1016/j.resp.2013.03.01323548823Search in Google Scholar

38. Crohns M, Liippo K, Erhola M, Kankaanranta H, Moilanen E, Alho H et al. Concurrent decline of several antioxidants and markers of oxidative stress during combination chemotherapy for small cell lung cancer. Clinical Biochemistry 2009; 42: 1236–45.10.1016/j.clinbiochem.2009.05.00319445914Search in Google Scholar

39. Zhou J, Zhu Q, Yao H. Chemotherapy of non-small-cell lung cancer (NSCLC) and changes in serum sAPO-1/Fas and nitric oxide (NO) levels. Chin J Onc 2000; 22: 225–7.Search in Google Scholar

40. Colakogullari M, Ulukaya E, Yilmaztepe A, Ocakoglu G, Yilmaz M, Karadag M et al. Higher serum nitrate levels are associated with poor survival in lung cancer patients. Clinical Biochemistry 2006; 39: 898–903.10.1016/j.clinbiochem.2006.06.00816919616Search in Google Scholar

41. Conklin KA, Nicolson GL. Molecular replacement in cancer therapy: reversing cancer metabolic and mitochondrial dysfunction, fatigue and the adverse effects of cancer therapy. Curr Cancer Ther Rev 2008; 4: 66-76.10.2174/157339408783565484Search in Google Scholar

42. Deavall DG, Martin EA, Horner JM, Roberts R. Drug-induced oxidative stress and toxicity. J Toxicol. 2012; 645460 DOI: 10.1155/2012/645460.10.1155/2012/645460342013822919381Search in Google Scholar

43. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.10.1016/j.ejphar.2014.07.025414668425058905Search in Google Scholar